Lead Product(s): Cannabinol
Therapeutic Area: Dermatology
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2020
InMed Pharmaceuticals, revealed the rare cannabinoid cannabinol as the active pharmaceutical ingredient in its two product candidates under development: INM-755 for epidermolysis bullosa and INM-088.